Arkolith/Insider Trading/JANX/Form 4

Campbell David Alan

President and CEO, DirectorJanux Therapeutics, Inc. (JANX) · full profile →Form 4 · filed Jan 2, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$111K
Net Open-Market Flow
-$111K
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jan 2, 2026Grant(A)97K—$0382K
Jan 2, 2026Sell(S)8K$13.73$111K285K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jan 2, 2026Grant(A)338K—$0338K

Transaction Codes

A
Grant / award
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001864158-26-000002) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML